Pleural resection and pleural infusion chemotherapy for therapy of malignant pleural mesothelioma

Genet Mol Res. 2014 Jan 21;13(1):483-9. doi: 10.4238/2014.January.21.17.

Abstract

The aim of this study was to evaluate effective treatment methods of malignant pleural mesothelioma (MPM). Twenty-three patients with MPM were cured by pleural infusion chemotherapy after surgery. Median survival time and the 1-, 2-, and 3-year survival rates were analyzed on the basis of follow-up. Median survival time of all patients was 15 months (range: 3 to 89 months); the 1-, 2-, and 3-year survival rates were 69.6, 43.5, and 13.0%, respectively. The 1-year survival rates of patients in stages I, II, and III were 83.3, 62.5, and 33.3%, respectively, the 2-year survival rates were 50, 37.5, and 33.3%, respectively, and the 3-year survival rates were 34, 23, and 0%, respectively. Surgery-oriented comprehensive treatment was adopted for MPM, which could improve the prognosis and life quality of patients to some extent.

Publication types

  • Clinical Trial

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / therapeutic use*
  • Carboplatin / administration & dosage
  • Carboplatin / therapeutic use*
  • Disease-Free Survival
  • Female
  • Follow-Up Studies
  • Humans
  • Infusions, Parenteral
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / surgery
  • Male
  • Mesothelioma / drug therapy*
  • Mesothelioma / surgery
  • Mesothelioma, Malignant
  • Middle Aged
  • Paclitaxel / administration & dosage
  • Paclitaxel / therapeutic use*
  • Postoperative Period

Substances

  • Antineoplastic Agents
  • Carboplatin
  • Paclitaxel